
This zzso phase I, zzso study assessed the zzso dose zzso safety, zzso and zzso activity of zzso in combination with zzso in patients with advanced solid zzso 

zzso zzso zzso or 50 zzso was administered orally once daily on three dosing zzso 4 weeks on treatment, 2 weeks off treatment zzso zzso 2 weeks on treatment, 1 week off treatment zzso zzso and continuous daily dosing zzso zzso zzso zzso 1,000, or 1,250 zzso was administered orally twice daily on days 1 to 14 every 3 weeks for all zzso zzso and zzso doses were escalated in serial patient zzso 

zzso patients were zzso Grade 3 adverse events included abdominal pain, zzso zzso fatigue, zzso and zzso zzso The zzso for Schedule zzso and the zzso schedule was zzso zzso zzso plus zzso 1,000 zzso twice per day; the zzso for Schedule zzso was zzso 50 zzso plus zzso 1,000 zzso twice per zzso There were no clinically significant zzso zzso zzso Nine partial responses were confirmed in patients with pancreatic cancer zzso zzso 3) and breast, zzso zzso zzso and zzso cancer, and zzso (each zzso zzso zzso 

The combination of zzso and zzso resulted in an acceptable safety profile in patients with advanced solid zzso Further evaluation of zzso in combination with zzso may be undertaken using the zzso for any of the three treatment zzso 

